Table 2.
Age standardized study population characteristic by subtypes of cases in means (standard deviations) or percents, Cancer of the Prostate Sweden Study
| Fatal | Advanced | Localized | High grade | Low grade | |
|---|---|---|---|---|---|
| N | 307 | 499 | 1020 | 231 | 693 |
| FRAP diet (mmol/d) | 21.6 (7.9) | 22.5 (8.9) | 22.2 (8.1) | 21.3 (8.0) | 22.3 (8.0) |
| FRAP fruit/vegs (mmol/d) | 3.5 (1.9) | 3.4 (1.7) | 3.5 (1.7) | 3.6 (2.0) | 3.4 (1.6) |
| FRAP suppl. (mmol/d) | 0.7 (1.2) | 0.8 (1.4) | 0.9 (1.4) | 0.9 (1.3) | 0.8 (1.4) |
| Age | 67.0(7.3) | 68.6 (7.4) | 66.0 (7.1) | 68.3 (7.4) | 65.4 (7.0) |
| BMI | 26 (3) | 26 (3) | 26 (3) | 26 (3) | 26 (4) |
| Current smokers (%) | 14 | 13 | 10 | 12 | 10 |
| Never smokers (%) | 42 | 39 | 39 | 41 | 38 |
| 0–9 years education (%) | 53 | 51 | 44 | 48 | 44 |
| 10–12 years education (%) | 37 | 41 | 40 | 40 | 41 |
| 13+ yrs education (%) | 10 | 8 | 17 | 13 | 16 |
| Energy kcal/d) | 2363 (701) | 2334(681) | 2270 (630) | 2387(655) | 2234 (624) |
| Coffee (cups/day) | 3.1 (1.8) | 3.2(2.0) | 3.1 (1.9) | 3.0 (1.9) | 3.1 (1.8) |
| Tea (cups/day) | 0.5 (0.8) | 0.5 (0.9) | 0.7 (1.1) | 0.6 (0.8) | 0.7 (1.1) |
| Chocolate (serv./d) | 0.2 (0.3) | 0.2 (0.3) | 0.2 (0.2) | 0.2 (0.2) | 0.2 (0.2) |
| Berries (serv./d) | 0.2 (0.3) | 0.2 (0.2) | 0.2 (0.3) | 0.2 (0.3) | 0.1 (0.2) |
| Boiled potatoes (serv./d) | 0.6(0.4 | 0.6 (0.4) | 0.6 (0.4) | 0.6 (0.3) | 0.6 (0.4) |
| Multivitamin use (%) | 21 | 22 | 21 | 29 | 20 |
| Vitamin C suppl. use (%) | 12 | 15 | 15 | 16 | 14 |
| Vitamin E suppl. use (%) | 3 | 3 | 4 | 3 | 5 |
| Calcium (mg/d) | 1241(406) | 1222 (390) | 1188 (363) | 1213 (381) | 1193 (363) |
| Zinc (mg/d) | 11.5 (1.9) | 11.5 (1.9) | 11.6 (1.9) | 11.6 (1.9) | 11.7 (1.8) |
| PSA at diagnosis | 264 (573) | 276 (665) | 39 (241) | 167 (364) | 22 (136) |
Fatal prostate cancer: Death from prostate cancer through follow up. Advanced prostate cancer: M1, N1, T3 or T4 and death during follow up. Localized prostate cancer: T1 or T2 and N0/M0. High-grade prostate cancer: Gleason sum 8–10. Low-grade prostate cancer: Gleason sum 2–6